Replies to post #192036 on Biotech Values

[Double_Bagel]

Why couldn't HALO's technology be used to extend the duration of a subcutaneous drug such as Humira?

If it did and HALO/ABBV are successful in getting this approved, how many additional years of patent protection would this improved version of Humira have?

What would that mean to biosimilars of Humira (MNTA)?

Would you be a buyer of ABBV or HALO on this news?

I am long HALO both in my real-money portfolio and in the SI Biotech contest portfolio :-)